IRIS
ADAMO, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 14.048
NA - Nord America 11.528
AS - Asia 6.241
SA - Sud America 2.096
AF - Africa 179
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 13
Totale 34.120
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.300
RU - Federazione Russa 6.996
SG - Singapore 2.708
BR - Brasile 1.820
CN - Cina 1.790
IE - Irlanda 1.625
SE - Svezia 1.612
IT - Italia 792
HK - Hong Kong 679
DE - Germania 572
PL - Polonia 524
UA - Ucraina 504
FR - Francia 498
GB - Regno Unito 311
FI - Finlandia 294
VN - Vietnam 286
IN - India 194
AR - Argentina 104
CA - Canada 104
BD - Bangladesh 86
BE - Belgio 73
MX - Messico 69
IQ - Iraq 63
AT - Austria 61
ZA - Sudafrica 60
JP - Giappone 58
TR - Turchia 53
CO - Colombia 43
ID - Indonesia 41
EC - Ecuador 40
ES - Italia 36
UZ - Uzbekistan 35
VE - Venezuela 32
NL - Olanda 31
PK - Pakistan 31
MA - Marocco 30
PH - Filippine 22
KE - Kenya 19
SA - Arabia Saudita 18
TN - Tunisia 18
AE - Emirati Arabi Uniti 17
NP - Nepal 17
CZ - Repubblica Ceca 16
AL - Albania 14
PY - Paraguay 14
AZ - Azerbaigian 13
CL - Cile 13
IL - Israele 13
JO - Giordania 13
DO - Repubblica Dominicana 12
DZ - Algeria 12
EG - Egitto 12
JM - Giamaica 12
KG - Kirghizistan 12
LT - Lituania 12
MY - Malesia 12
KZ - Kazakistan 10
OM - Oman 10
PE - Perù 10
BO - Bolivia 9
IR - Iran 9
CH - Svizzera 8
CR - Costa Rica 8
EU - Europa 8
PS - Palestinian Territory 8
UY - Uruguay 8
AU - Australia 7
BG - Bulgaria 7
HN - Honduras 7
LB - Libano 7
LV - Lettonia 7
SK - Slovacchia (Repubblica Slovacca) 7
TH - Thailandia 7
CI - Costa d'Avorio 6
HR - Croazia 6
RO - Romania 6
RS - Serbia 6
AO - Angola 5
GE - Georgia 5
HU - Ungheria 5
NI - Nicaragua 5
NZ - Nuova Zelanda 5
XK - ???statistics.table.value.countryCode.XK??? 5
BA - Bosnia-Erzegovina 4
DK - Danimarca 4
ET - Etiopia 4
AM - Armenia 3
BN - Brunei Darussalam 3
GA - Gabon 3
GR - Grecia 3
GT - Guatemala 3
LU - Lussemburgo 3
MN - Mongolia 3
NO - Norvegia 3
PA - Panama 3
SN - Senegal 3
SY - Repubblica araba siriana 3
A2 - ???statistics.table.value.countryCode.A2??? 2
EE - Estonia 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 34.088
Salva come PNG Salva come JPEG
Città #
Moscow 2.045
Dublin 1.619
Ashburn 1.568
Singapore 1.507
Chandler 1.366
Dallas 1.075
Jacksonville 1.010
Nyköping 847
Hong Kong 677
Beijing 637
San Jose 528
Warsaw 507
New York 349
The Dalles 326
Ann Arbor 276
Princeton 271
Los Angeles 263
Medford 258
Dearborn 250
Cambridge 239
Lauterbourg 229
Des Moines 212
Messina 172
Boardman 166
São Paulo 148
Buffalo 136
Tianjin 96
Munich 93
Woodbridge 85
Council Bluffs 83
Jinan 83
Frankfurt am Main 79
Ho Chi Minh City 73
Brussels 71
Lancaster 70
Hanoi 69
Pune 61
Wilmington 60
Orem 56
Rio de Janeiro 56
Shenyang 55
Redondo Beach 54
San Mateo 54
Belo Horizonte 52
Tokyo 49
Guangzhou 48
Vienna 47
Brooklyn 46
Dong Ket 46
Nanjing 42
Santa Clara 42
Chennai 41
Houston 36
Johannesburg 36
Hebei 34
Montreal 34
San Francisco 34
London 33
Zhengzhou 33
Brasília 32
Tashkent 32
Turku 30
Nuremberg 29
Seattle 28
Porto Alegre 27
Shenzhen 27
Stockholm 27
Helsinki 26
Chicago 25
Haikou 25
Jakarta 25
Shanghai 25
Manchester 24
Boston 23
Hangzhou 23
Milan 23
Atlanta 22
Baghdad 22
Campinas 22
Mumbai 22
Denver 21
Mexico City 21
Nanchang 21
Rome 21
Changsha 20
Goiânia 20
Leawood 19
Ningbo 19
Quito 19
Taizhou 19
Toronto 19
Curitiba 18
Jiaxing 18
Nairobi 18
Amsterdam 17
Düsseldorf 17
Guarulhos 17
Washington 17
Ankara 16
Hyderabad 16
Totale 19.444
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 428
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 243
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery 236
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 234
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study 233
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 223
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 217
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 217
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 214
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 211
Correction to: Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 207
An immunohistochemical investigation of pre-metastatic niche (PMN) in node-negative invasive breast carcinomas 204
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 204
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 202
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 199
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 196
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 194
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 194
[Serum levels of copper and zinc in patients with lung cancer] 191
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 191
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 188
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 187
Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup 186
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 185
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINE + VINORELBINE IN ADVANCED NSCLC EDERLY PATIENTS .PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY(MILES) RANDOMIZED TRIAL 184
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 183
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 181
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 181
Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 181
Intralesional sonographically guided injections of lymphokine- activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: A pilot study 180
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 179
Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors 179
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 179
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen 178
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 175
HER-2 overexpression in advanced node-positive gastric carcinomas: is there any relationship with other clinico-pathological histoprognostic parameters? 175
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 173
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 173
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 173
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 171
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 171
Breast. La terapia primaria: stato dell'arte 171
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 171
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 171
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 171
The treatment of peritoneal carcinomatosis in elderly patients. 170
Biological parameters in breast cancer. 170
Detection Of Lynphocytic β - Endorphin In Cancer Patients During Hospedalization And After In Vitro Culture With IL 2. 170
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 168
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 167
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 166
AIOM Conference 2004. Docetaxel: a recent conquest in the adjuvant therapy of breast cancer 166
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 166
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 166
Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). 166
Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. 166
Extended RAS mutation testing on wild-type KRAS exon 2 metastatic colorectal cancer. 166
FCM detection of lymphocytic beta-endorphin in cancer patients during hospitalization and after in vitro culture with IL2 165
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 165
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 165
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 164
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 164
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 164
Unusual relapse of hepatocellular carcinoma 164
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 164
Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica 163
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 163
SPONTANEOUS TRANSFORMATION AND IMMORTALIZATION OF PERITONEAL- MACROPHAGES OF HUMAN-ORIGIN 163
Safety of Capecitabine plus Bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC) 162
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 162
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 162
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 161
CyberKnife Radiosurgery Alone or Combined with "Dose Dense" Temozolomide Administration for Recurrent Gliomas. 159
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 159
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 158
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 158
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 157
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 156
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 155
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 155
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 155
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 154
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries 154
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 154
Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site of disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy 153
TCC superficiale della vescica: identificazione nel sedimento urinario di mediatori di proliferazione cellulare quali possibili indici di recidiva e progressione neoplastica. 153
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. 152
Peritoneal carcinomatosis of colorectal origin. 152
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 150
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 150
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. 149
Liquid biopsy tracking of lung tumor evolutions over time 149
First Line Chemotherapy with Oral Vinorelbine (oV) in Elderly Hormone-Refractory Prostate Cancer (HRPC) Patients (pts 148
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 148
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 148
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 147
RANDOMISED PHASE II TERTIARY CHEMOPREVENTION TRIAL FOR COLORECTAL ADENOMA IN 24 PATIENTS WITH COLORECTAL CANCER TREATED WITH CELECOXIB 146
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 146
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 146
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 145
Totale 17.598
Salva come PNG Salva come JPEG
Categoria #
all - tutte 109.399
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.399
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021131 0 0 0 0 0 0 0 0 0 0 0 131
2021/20221.772 19 244 30 45 58 16 106 63 15 320 265 591
2022/20235.013 389 493 216 417 379 512 80 325 1.984 19 141 58
2023/20241.301 101 186 69 108 71 498 66 56 5 46 11 84
2024/20255.070 66 47 92 313 258 168 106 1.119 1.341 292 416 852
2025/202615.308 751 924 1.075 857 1.249 3.559 1.978 2.029 1.902 556 219 209
Totale 34.406